43 results about "Lung Inflammations" patented technology

The application discloses an FPR1 polypeptide blocker against lung inflammation and application thereof. The application provides a polypeptide shown in Sequence NO. 1, which can significantly improve lung tissue structure damage of a lung inflammation model mouse, reduce a proinflammatory factor level, reduce neutrophil infiltration, and show obvious anti-lung inflammation efficacy. Therefore, the polypeptide shown in Sequence NO. 1 has a prospect of development into an anti-lung inflammation drug.

This invention provides an application of the peptide Nod-T3 in the preparation of drugs for treating lung diseases. The Nod-T3 peptide is derived from human protein and has a significant inhibitory effect on chronic lung inflammation and fibrosis caused by smoking. It can be used to treat COPD and other smoking-related lung diseases. It also has high biocompatibility and low toxicity, and has the potential and development value to become a new type of peptide drug.

The invention discloses a preparation method and application of bioactive lipid and lipid nanoparticles thereof. The bioactive lipid molecule is formed by bonding long-chain fatty acid (LCFA) with different chain lengths with two functional small molecules, namely phenylboronic acid pinacol ester (PBAP) and Tempol (Tpl) respectively, so that two types of lipid molecules, namely PBAP-LCFA and Tpl-LCFA, with anti-inflammatory activity are constructed. The lipids are used as functional components, and the anti-inflammatory lipid nanoparticles with good biocompatibility, including PLP, TLP and TPLP, can be prepared through a film dispersion method. The lipidoid and the lipid nanoparticles are simple and convenient in preparation process, controllable in structure and function and easy for large-scale production, and have treatment potential in various acute and chronic inflammatory diseases. In an animal model, the lipid nanoparticles have remarkable curative effects on acute peritonitis, acute lung injury, acute hepatic failure, asthma and other diseases. Besides, the lipid bilayer structure of the TPLP can efficiently entrap hydrophilic / hydrophobic drugs, can synergistically deliver treatment drugs while exerting the anti-inflammatory effect of the TPLP, and realizes a synergistic combined treatment strategy for chronic lung inflammation and other diseases.

The application relates to kaempferol cerium nanoparticles and a preparation method and application thereof, and belongs to the technical field of biological medicines. The kaempferol cerium nanoparticles are prepared by performing coordination co-assembly on kaempferol and cerium ions in the presence of polyethylene glycol at a specific molar ratio, and the nanoparticles have uniform particle sizes and good dispersity. The nanoparticles have the anti-inflammatory activity of kaempferol and the ROS scavenging capacity of cerium ions, and show a significant synergistic effect in in-vivo and in-vitro experiments, can effectively reduce lung inflammation, inhibit oxidative stress, improve lung function, and have good biological safety, thereby providing a new drug candidate scheme for the treatment of ARDS.

This invention belongs to the field of biomedical technology, specifically relating to a rapid purification method for umbilical cord MSC exosomes and their application in the preparation of drugs for treating COPD. This invention discloses a method for rapidly purifying umbilical cord mesenchymal stromal cell (MSC) exosomes and a pharmaceutical composition comprising umbilical cord MSC exosomes and yamosaponin. In this pharmaceutical composition, the umbilical cord MSC exosomes and yamosaponin synergistically enhance the dynamic compliance of COPD rats, reduce airway resistance, decrease pulmonary inflammation, and repair pulmonary dysfunction. This invention provides a new technical solution for the preparation of drugs for treating or improving COPD.

The invention provides oral streptococcus ZRSOR-5 as well as a related product, a method and application thereof. The preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention in the Guangdong Microbial Culture Collection Center is GDMCC No: 65352, and the preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention is CGMCC No: 65352. Experiments prove that the SOR preparation is prepared by diluting the SOR preparation with normal saline and inhaling the SOR preparation into mice in advance, so that the survival rate of influenza virus infected mice can be remarkably increased, and lung inflammation and virus load can be reduced. When the ZRSOR-5 preparation provided by the invention is used in advance, pneumonia caused by influenza viruses can be resisted.

The invention discloses an application of glucopyranose galactooligosacharide in preparation of a medicine for treating and / or preventing allergic asthma. The invention finds that the glucopyranose galactooligosaccharide can obviously relieve airway inflammatory reaction of an allergen-induced allergic asthma model, including reducing airway inflammatory factor level, improving airway hyperreactivity and reducing lung inflammatory cell infiltration, and has no abnormal influence on blood routine and main organ functions; the composition has the advantages of small drug application dosage, low pharmaceutical cost, high safety, remarkable drug effect and the like, and has a wide application prospect.

A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.

The invention relates to a system for measuring a level of a subject's immune activity (10), the system comprising: - an exhaled air sensor (20), - a device for measuring exhaled air (30), - computation means (40) suitable for determining data relating to the air exhaled by the subject from the measurements carried out by the device (30), - a memory (60) suitable for storing the measurements performed by the device (30) and / or the data calculated by the means (40), and the subject's personal data, - a computation means (70) suitable for determining a level of the subject's immune activity on the basis of at least one item of exhaled air data, generated in real time by the means (40) and / or stored in the memory (60), - a communication and management interface (80) suitable for presenting said level of the subject's immune activity and / or sub-scores of immunological activity, inflammatory activity, digestive inflammation and / or pulmonary inflammation.

The invention provides a pollen vaccine based on an aluminum-CpG composite adjuvant and application of the pollen vaccine. The pollen vaccine comprises an aluminum-CpG chemical coupling nano adjuvant and a recombinant mugwort main allergen, the adjuvant is a substance formed by coupling an aluminum oxygen hydride nanorod and CpG through an amido bond, carboxyl on the surface of an AlOOH nanorod is activated, and then the AlOOH nanorod reacts with aminated CpG ODN to obtain the adjuvant. Stable combination of the aluminum salt nanoparticles and CpG ODN is achieved through chemical coupling, the coupling efficiency is larger than or equal to 95%, cytotoxicity is avoided, the problems that in traditional physical mixing, the aluminum salt nanoparticles and CpG ODN are not synergistic in effect and prone to dissociation are solved, and the synergistic immunoregulation effect of adjuvant components is ensured; after the adjuvant is loaded with the Artemisia pollen allergen Art v1, the IgE level can be remarkably reduced, lung inflammation can be relieved, allergic symptoms can be improved in treatment and prevention models, and a novel adjuvant platform is provided for immunotherapy of pollen allergy.

The invention provides a spanishneedles herb exosome as well as a preparation method and application thereof in acute lung injury, and belongs to the technical field of biological medicines. According to the preparation method of the spanishneedles herb exosome provided by the invention, the spanishneedles herb exosome can be extracted from a plant source through a simple method. In one embodiment of the invention, a lung injury model constructed by using LPS is used as an experimental animal to verify the therapeutic effect of the spanishneedles herb exosome. Results show that after the spanishneedles herb exosome is used for treatment, mouse lung tissue injury and inflammatory cell exudation can be relieved, and lung injury caused by LPS can be relieved; tNF-alpha and IL-1beta in lung lavage fluid of a mouse are remarkably reduced, and lung inflammation infiltration of the mouse can be relieved. Therefore, the spanishneedles herb exosome has the effect of treating the acute lung injury and can be used for preparing the medicine for treating the acute lung injury.

The invention relates to an application of Fgl2 gene knockout in antagonism of new coronavirus. In the technical scheme provided by the invention, a new crown infected mouse model is established through two SARS-CoV-2 mouse adaptive strains, namely, an MA17 strain and an MASCp36 strain, and it is verified that virus infection can promote Fgl2 expression up-regulation and fibrinogen deposition in mouse lung tissues; in addition, an SARS-CoV-2 mouse adaptive strain MA17 is utilized to infect an Fgl2 gene knockout mouse to prove that the Fgl2 gene knockout can antagonize lung inflammation infiltration, tissue damage, thromboembolism, fibrinogen deposition and fibrosis formation caused by virus infection, so that the occurrence of severe case and death of the mouse is reduced.

The invention provides a ganoderma lucidum molecular ecological liquid extract obtained through specific fermentation and a preparation method and application thereof, and belongs to the technical field of microbial fermentation. According to the method, an improved fermentation culture medium is adopted, 5-8% of CO2 is introduced, fermentation is performed for 90-180 days at the temperature of 30-32 DEG C under the condition that the concentration of dissolved oxygen in the environment is kept to be 20-30%, and after purification, the extract of the ganoderma lucidum molecular ecological liquid is obtained. According to the myxomycete molecular ecological liquid prepared by the preparation method provided by the invention, the content of active ingredients for relieving the symptoms of the chronic obstructive pulmonary disease can be remarkably increased; moreover, an in-vitro cell experiment verifies that the extract of the ganoderma lucidum molecular ecological liquid has an inhibition effect on an A549 cell line, and an animal experiment further proves that the extract of the ecological liquid can regulate and control the expression level of proinflammatory cytokines, so that lung inflammation is inhibited, pathological injury of lung tissues is relieved, and local abnormal conditions of the lung are improved.

Part of this invention provides novel small molecule PHD inhibitors having structures according to formula (I) and its derivatives: or pharmaceutically acceptable salts thereof. The compounds provided herein may be used to treat the following diseases: including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory diseases (e.g., respiratory infections, acute respiratory distress syndrome), liver diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute kidney injury and chronic kidney disease), inflammatory bowel disease (IBD), ischemic-reperfusion injury (e.g., stroke), and retinopathy of prematurity (ROP).

The invention discloses an andrographolide-based pH / ROS (Potential of Hydrogen / Reactive Oxygen Species) double-response double-drug loaded nano material as well as preparation and application thereof. The material is composed of an amphiphilic polymer (PEG-fan-shaped lysine-formyl phenylboronic acid) and hydrophobic drugs A and B, the drug A is covalently bound with the polymer through a borate bond to form a prodrug, and the drug B is physically wrapped in a nanoparticle hydrophobic core. The acidity and high reactive oxygen species (ROS) microenvironment of inflammatory lesions are utilized to trigger breakage of a Schiff base bond and a borate bond in a molecular chain, and the nanoparticles are induced to be disassembled and synergistically release double drugs. According to the invention, the enrichment degree and bioavailability of the drug at the lung inflammation part are obviously improved through passive targeting, efficient inhibition of inflammatory factor storm is realized, and a new scheme is provided for accurate delivery of hydrophobic anti-inflammatory drugs.

Disclosed herein are small anti-inflammatory peptides for blocking NF-κB. The peptides and compositions including the peptides can be administered to inhibit cytokine production and / or to inhibit lung inflammation in individuals in need thereof. Particular embodiments include administration to individuals suffering from coronavirus disease 2019 (COVID-19).

The application discloses a kind of based on CLDN1 protein's derivative peptide, fusion protein and its application, the derivative peptide includes the amino acid sequence as shown in SEQ ID NO:3, the amino acid sequence of the fusion protein is as shown in SEQ ID NO:2.The application finds that several derivative peptides containing CLDN1 protein extracellular loop EL1 peptide segment have significant inhibitory effect on various RNA and DNA envelope viruses.The fusion protein shows significant in vivo antiviral activity, can alleviate lung inflammation caused by RSV infection, and reduce viral nucleic acid level.Therefore, the derivative peptide and fusion protein based on CLDN1 protein designed in the application can be used for antiviral therapy or prophylactic drug research and development, and have wide application prospect.

The invention belongs to the technical field of biological medicines, and particularly discloses a polypeptide for protecting lung vascular endothelial cells and relieving lung injury and application of the polypeptide. The polypeptide is Humanin-G (HNG), and the amino acid sequence of the polypeptide is MAPRGFSCLLLLTGEIDLPVKRRA. The polypeptide is targeted to mitochondria of pulmonary vascular endothelial cells, provides protection from energy supply and cell survival roots, and has profound significance in improving functions of the pulmonary vascular endothelial cells and reducing the death rate of sepsis-induced acute lung injury (ALI). Researches show that when the polypeptide is used in the acute injury stage, lung inflammation of a model animal can be relieved by 25%-50%, the lung injury HE score can be reduced by about 50%, pulmonary edema can be relieved by about 30%, mitochondrial functions can be recovered by about 70%, the ATP yield can be increased by 30%, and the effect is excellent. Therefore, the invention provides a brand new strategy for maintaining the mitochondrial homeostasis by using the polypeptide so as to relieve lung injury.

A method for preparing inhalable targeted gold nanoparticles for accelerated lung delivery and treating lung inflammation is provided. The method includes preparing plasmids; performing plasmids transformation; performing protein expression induction; performing protein purification; and preparing spike RBD-conjugated gold nanoparticles (Au@PEG-RBD NPs). The airborne NP preferentially accumulates in lungs with lipopolysaccharides-induced ARDS to healthy lungs and enters alveolar epithelial cells that express angiotensin converting enzyme (ACE) 2 and L-SIGN, both Spike receptors activated in ARDS hamsters. The NP treats tissue injury, oxidative stress, and inflammation more effectively than corticosteroids, without gold retention in major organs or toxicity 1-year post-inhalation. The gold core blocks p38α mitogen-activated protein kinase and polo-like kinase 3. Similar efficacy is observed in hamsters with hydrochloric acid-induced ARDS. The self-therapeutic NPs, when combined with bioinspiration and non-invasive delivery, provide a safe, effective, and targeted treatment for lung inflammation.

The invention relates to application of a palmitoylation modification inhibitor in preparation of a medicine for treating or relieving allergic airway inflammation. The palmitoylation modified inhibitor is applied to the field of treatment of allergic airway inflammatory diseases for the first time. Experimental results show that the inhibitor can significantly inhibit activation of a JAK1 / STAT6 signal channel in vitro and effectively inhibit secretion of Th2 type inflammatory factors such as IL-4 and IL-13 by eosinophilic granulocytes; in animal model research, the palmitoylation modification inhibitor can obviously relieve allergic airway inflammatory reaction of mice, and the allergic airway inflammatory reaction is specifically shown as reduction of the number of eosinophils in bronchoalveolar lavage fluid (BALF), reduction of expression and secretion levels of BALF and lung tissue Th2 type inflammatory factors and obvious relieving of lung inflammation pathological degree. The invention provides a theoretical basis and a potential target for clinically developing a novel therapeutic drug for allergic airway inflammatory diseases in the future.

The invention discloses application of inhibition of RUNX3 gene expression in preparation of medicines for preventing or treating silicosis, and belongs to the technical field of biological medicines. In-vivo and in-vitro silicosis models prove that the RUNX3 has high specificity expression in the silicosis process and is a key factor for driving disease progression. By inhibiting the expression of RUNX3 through a gene knock-down technology, silica-induced lung inflammation infiltration and collagenous fiber deposition can be significantly reduced, and the expression levels of key inflammatory factors (IL-1beta, IL-6 and TNF-alpha) and fibrosis indexes (Collagen I, Collagen III and Fibronectin) can be effectively down-regulated. Therefore, any substance capable of specifically inhibiting the expression of the RUNX3 gene, including but not limited to siRNA, shRNA, antisense oligonucleotide, ribozyme, microRNA and an inhibitor targeting the gene promoter thereof, can be used for developing the pharmaceutical composition for preventing or treating silicosis.

This invention belongs to the field of traditional Chinese medicine application technology and provides an application of a traditional Chinese medicine composition in the treatment of radiation-induced pneumonia. The traditional Chinese medicine composition is made from bamboo sap and *Trifolium repens*; the mass ratio of bamboo sap to *Trifolium repens* is (1-10):(1-10). Radiation-induced pneumonia refers to lung inflammation caused by radiotherapy for malignant tumors of the chest. The traditional Chinese medicine composition provided by this invention has the effects of clearing heat and detoxifying, resolving phlegm and dissipating nodules. It has a simple composition and high safety, providing a new option for the treatment of radiation-induced pneumonia.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a thymic stromal lymphopoietin (TSLP) gene. The TSLP RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an TSLP gene. Pharmaceutical compositions that include one or more TSLP RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described TSLP RNAi agents to pulmonary cells, in vivo, provides for inhibition of TSLP gene expression, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as asthma, including allergic asthma.

Provided herein are polypeptides including an amino acid sequence having at least 70% sequence identity with an Isthmin 1 (ISM1) protein or a GRP78-activating fragment thereof, as well as expressible nucleic acids encoding said polypeptides. Uses of such agents, as well as methods for inducing apoptosis in alveolar macrophages and / or for treating, ameliorating, or preventing inflammation or lung disease such as chronic obstructive pulmonary disease (COPD), emphysema, asthma, acute lung injury (ALI), lung fibrosis, and / or acute respiratory distress syndrome.

The invention relates to an application of an E-TMED10 inhibitor in preparation of a product for treating and / or preventing inflammation. The interaction between the E protein of the coronavirus and the TMED10 (E-TMED10) is a potential molecular mechanism for driving the coronavirus-induced excessive inflammation, and is also a potential therapeutic target for resisting the harmful effect of the coronavirus-induced inflammation. The interaction between the coronavirus E protein and the TMED10 is blocked or reduced, so that the effects of reducing the release of proinflammatory factors and relieving lung inflammation can be realized.

This invention provides the use of a trisaccharide compound with a core structure of Glc(1→4)IdoA(1→4)GlcNS in the preparation of a drug for treating or preventing asthma. This compound can reduce lung inflammation in asthma model mice, reduce mucus production in the trachea, and effectively improve ventilation.

The application discloses a mucus-dissolving inhalable dry powder for pulmonary RNA delivery and a preparation method and application thereof, and belongs to the technical field of biological medicines. The mucus-dissolving inhalable dry powder provided by the application is based on chitosan, can load RNA drugs as a carrier, and can graft DNA enzyme on the surface of the chitosan, so as to decompose a pulmonary mucus barrier and promote the penetration of substances. Finally, the inhalable dry powder with good aerodynamic performance is prepared through freeze spray drying, so as to realize effective deposition in a pulmonary lesion site. On the other hand, the DNA enzyme can be used as a therapeutic drug to reduce pulmonary inflammation, and forms a double-acting therapeutic effect with the loaded RNA drug. The application provides a new type of efficient and precise inhalable delivery system for pulmonary delivery of RNA drugs, and has a wide application prospect in the pulmonary delivery of gene drugs.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof:or a pharmaceutically acceptable salt thereof.  The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g., respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI). 

The present disclosure relates to pravibismane compositions and their use in methods for treating inflammation-related diseases or conditions, such as an inflammatory disease of the lung, psoriasis, and acne vulgaris in a subject. Treatment of inflammation-related diseases and conditions according to the disclosed methods provides an increase in the expression of anti-inflammatory cytokines, including IL-10, and / or a decrease in the expression of one or more pro-inflammatory cytokines, such as one or more of IFN-γ, MIP-3a, MIP-1β, TNF-a, IL-22, IL-17A, IL-15, and IL-13.

The invention relates to a kaempferol cerium nanoparticle as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the invention, kaempferol and cerium ions are subjected to coordination and co-assembly in the presence of polyethylene glycol according to a specific molar ratio, such that nanoparticles with uniform particle size and good dispersibility are prepared. The nano-particles have the anti-inflammatory activity of kaempferol and the ROS removal capacity of cerium ions, show a remarkable synergistic effect in in-vivo and in-vitro experiments, can effectively relieve lung inflammation, inhibit oxidative stress and improve lung functions, are good in biological safety and provide a new drug candidate scheme for treatment of ARDS.